Our medicines
- Cardiovascular, Renal & Metabolism
  - Heart Failure
    - Forxiga® (Dapagliflozin)
  - Chronic Kidney Disease (CKD)
    - Forxiga® (Dapagliflozin)
  - Type 2 diabetes
    - Forxiga® (Dapagliflozin)
    - Xigduo® (Dapagliflozin/Metformin HCI)
  - Amyloidosis
    - Wainzua® (Eplontersen)
- Respiratory & Immunology
  - COPD
    - Trixeo® (Formoterol/Glycopyrronium/Budesonid)
  - Eosinophilic granulomatosis with polyangiitis (EGPA)
    - Fasenra® (Benralizumab)
  - Systemic lupus erythematosus (SLE)
    - Saphnelo® (Anifrolumab)
  - Asthma
- Oncology & Hematology
  - Breast Cancer
  - Hematology
    - Calquence® (Acalabrutinib)
  - Hepatocellular Carcinoma
    - Imfinzi® (Durvalumab) + Imjudo® (Tremelimumab)
  - Biliary Tract Cancer
    - Imfinzi® (Durvalumab)
  - Lung Cancer
  - Ovarian Cancer
    - Lynparza® (Olaparib)
  - Endometrial Cancer
    - Imfinzi® (Durvalumab)
  - Prostate Cancer
    - Lynparza® (Olaparib)
  - Muscle Invasive Bladder Cancer
    - Imfinzi® (Durvalumab)
  - Pancreatic Cancer
    - Lynparza® (Olaparib)
  - Gastric Cancer & Gastroesophageal adenocarcinoma (GC/GEJC)
    - Enhertu® (Trastuzumab Deruxtecan)
    - Imfinzi® (Durvalumab)
  - Tumor Agnostic
    - Enhertu® (Trastuzumab Deruxtecan)
- View all Medicines
Therapeutic Areas
- Cardiovascular, Renal & Metabolism
- Respiratory & Immunology
- Oncology
Contact us

Enter Search Term

Home
Products

Our products

errorMessage

requestToSignInContent

Cardiovascular, Renal & Metabolism
Respiratory & Immunology
Oncology & Hematology

Upon signing in, you will receive further information about our medications, such as study data, details on the mechanism of action, case studies, and patient profiles.

Forxiga^®

Chronic heart failure
Chronic kidney disease
Type-2 diabetes

Learn more

Forxiga^®
dapagliflozin
Learn more

Xigduo^®

Type-2 diabetes

Learn more

Xigduo^®
Dapagliflozin/Metformin HCl
Learn more

Upon signing in, you will receive further information about our medications, such as study data, details on the mechanism of action, case studies, and patient profiles.

Fasenra^®

Severe eosinophilic asthma

Eosinophilic granulomatosis with polyangiitis (EGPA)

Learn more

Fasenra^®
benralizumab
Login

Saphnelo^®

Systemic lupus erythematosus (SLE)

Learn more

Saphnelo^®
anifrolumab
Learn more

Symbicort^®

Asthma
Chronic obstructive pulmonary disease (COPD)

Learn more

Symbicort^®
Budesonid/Formoterol
Learn more

Tezspire^®

Severe asthma

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Learn more

TEZSPIRE^®
tezepelumab
Learn more

Trixeo^®

Chronic obstructive pulmonary disease (COPD)

Learn more

TRIXEO AEROSPHERE^®
Formoterol/Glycopyrronium/
Budesonid
Login

Upon signing in, you will receive further information about our medications, such as study data, details on the mechanism of action, case studies, and patient profiles.

Calquence^®

Mantle Cell Lymphoma (MCL)
Chronic Lymphocytic Leukemia (CLL)

Learn more

CALQUENCE^®
acalabrutinib
Login

Enhertu^®

Breast cancer
Gastric cancer
Solid Tumor

Learn more

ENHERTU^®
trastuzumab deruxtecan
Learn more

Lung cancer (SCLC & NSCLC)
Biliary tract cancer (BTC)
Hepatocellular carcinoma (HCC)
Gastric Cancer (GC)
Gastroesophageal Junction Cancer (GEJC)
Muscle-invasive Bladder Cancer (MIBC)
Endometrial Cancer

Learn more

IMFINZI^®
durvalumab
Login